Equities
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)2,586.00
  • Today's Change0.00 / 0.00%
  • Shares traded19.87k
  • 1 Year change-7.44%
  • Beta0.9080
Data delayed at least 20 minutes, as of Aug 23 2019 16:35 BST.
More ▼

Key statistics

On Friday, Genus PLC (GNS:LSE) closed at 2,586.00, -12.37% below its 52-week high of 2,950.94, set on May 16, 2019.
52-week range
Today
2,090.00Nov 20 20182,950.94May 16 2019
Markit short selling activity
Low
Med
High
Open2,624.00
High2,630.00
Low2,584.00
Bid--
Offer2,700.00
Previous close2,586.00
Average volume40.16k
Shares outstanding65.06m
Free float64.10m
P/E (TTM)--
Market cap1.68bn GBP
EPS (TTM)-0.1153
GBP
Annual div (ADY)26.80
GBX
Annual div yield (ADY)1.04%
Div ex-dateMar 07 2019
Div pay-dateApr 04 2019
Data delayed at least 20 minutes, as of Aug 23 2019 16:35 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Genus PLC shares was Hold at 2,180.00 on 28 Feb 2019Read the full article

Board of Directors

1/8

Bob Lawson, Non-Executive Chairman

2/8

Karim Bitar, Chief Executive

3/8

Stephen Wilson, Group Finance Director

4/8

Lysanne Gray, Non-Executive Director

5/8

Lykele van der Broek, Non-Executive Director

6/8

Lesley Knox, Senior Independent Director

7/8

Professor Ian Charles, Non-Executive Director

8/8

Dan Hartley, Group General Counsel and Company Secretary

Contact

Registered Office:
Genus plc
Matrix House
Basing View
Basingstoke
Hampshire
RG21 4DZ

Registered number: 2972325
T: +44(0)1256 347100
F: +44 (0)1256 477385

For all investor related enquiries, please contact:
Buchanan: Charles Ryland / Vicky Watkins: 

T: +44 (0) 207 466 5000
E: charlesr@buchanan.uk.com / victoriaw@buchanan.uk.com
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.